Contact information
+44 (0)1865 857501
Tracey Walker
patoruryholman@dtu.ox.ac.uk
https://orcid.org/0000-0002-1256-874X
Diabetes Trials Unit, OCDEM, Churchill Hospital, Old Road, Headington, OXFORD. OX3 7LJ
Rury Holman
MB, ChB. FRCP(Lon). FMedSci
Emeritus Professor of Diabetic Medicine
- Emeritus Diabetes Trials Unit Director
- Emeritus NIHR Senior Investigator
Rury Holman trained in medicine at the University of Bristol and was appointed Honorary Consultant Physician to the University of Oxford NHS Hospitals Trust in 1985, at which time he founded the University of Oxford Diabetes Trials Unit. He was appointed as the first Professor of Diabetic Medicine at the University of Oxford in 1998 and as the founding Academic Chairman of the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM) in 2003. He is a Fellow of the Academy of Medical Sciences, an Emeritus NIHR Senior Investigator and Emeritus Professor of Diabetic Medicine. Professor Holman has won many distinguished international awards including the ADA Harold Rifkin Award for Distinguished International Service, the ADA Outstanding Achievement in Clinical Diabetes Research Award, the Diabetes UK Banting Memorial Lecture, the Diabetes UK Robert Turner Award for Research Impact and the ADA Banting Medal for Scientific Achievement Award.
Recent publications
-
Proteomic pathways across the ejection fraction spectrum in patients with heart failure and diabetes mellitus: an EXSCEL trial substudy
Journal article
Peters AE. et al, (2025), Scientific Reports, 15
-
International Variation in Case Fatality After Major Coronary or Cerebrovascular Events in Individuals With Type 2 Diabetes: Evidence From ADVANCE, TECOS, and EXSCEL
Journal article
Clarke PM. et al, (2025), Diabetes Care
-
Validation of a treatment selection algorithm for optimal choice of SGLT2 and DPP4 inhibitor therapies in people with type 2 diabetes across major UK ethnicity groups
Preprint
Güdemann LM. et al, (2025)
-
Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects.
Journal article
Chadwick J. et al, (2025), J Clin Pharmacol
-
Response to Comments on Maddaloni et al. Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. Diabetes Care 2025;48:235-242.
Journal article
Maddaloni E. et al, (2025), Diabetes Care, 48, e61 - e62